COURSE DEVELOPED FOR PEOPLE WITH INTELLECTUAL DISABILITY TO LEARN ABOUT RESEARCH Inclusive research used by Scope Australia to support advocacy for change through lived experience
With
Dr Caroline Hart,
Senior Research Officer
Scope Australia
Nell Buchanan,
Research Assistant
Scope Australia
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | March 2026
Scope Australia is one of the largest not-for-profit disability service providers in Australia, supporting thousands of people with complex intellectual, physical, and multiple disabilities.
They operate across Victoria and New South Wales across more than 425 service locations.
Scope’s research team developed a course about what research is and how to do research. Eight people with intellectual disability did the course. Five people took part in interviews to help Scope learn about the course and how to make it better.
In November 2025, A/Professor Stella Koritsas, Scope’s Head of Research, Dr Caroline Hart, Senior Research Officer, and Mimari Hartono, Research Assistant, presented findings from their research into co-research as part of this week’s Australasian Society for Intellectual Disability 2025 conference — research carried out “with” or “by” people with disability rather than “to”, “about” or “for” them, which is important because it helps the sector uphold the United Nations Conventions on the Rights of Persons with Disabilities principles of dignity, autonomy, and full participation.
The research found that the course had a positive impact on people that extended beyond their ability to do and lead research. People who participated said that they felt more confident after the course and learned new skills. They also said that they made friends. They told Scope’s researchers that the course could be better if more easy English was used. They also wanted to be able to get to know people before the course started.
Australian Health Journal spoke with Dr Caroline Hart and Research Assistant Nell Buchanan, who explained what the courses means for the sector, plus the knowledge and experiences gained.
Source: Supplied and adapted
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
-
Adjunct Professor Alanna Geary talks Nursing Leadership
Adjunct Professor Alanna Geary FACN,
Chief Nursing & Midwifery Officer,
Metro North Hospital Hospital & Health Service, Queensland
talks Nursing Leadership -
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
